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Abstract 
Background: Adenosine stress perfusion cardiovascular magnetic resonance (CMR) is commonly used in the assess-
ment of patients with suspected ischaemia. Accepted protocols recommend administration of adenosine at a dose 
of 140 µg/kg/min increased up to 210 µg/kg/min if required. Conventionally, adequate stress has been assessed 
using change in heart rate, however, recent studies have suggested that these peripheral measurements may not 
reflect hyperaemia and can be blunted, in particular, in patients with heart failure. This study looked to compare stress 
myocardial blood flow (MBF) and haemodynamic response with different dosing regimens of adenosine during stress 
perfusion CMR in patients and healthy controls.
Methods: 20 healthy adult subjects were recruited as controls to compare 3 adenosine perfusion protocols: standard 
dose (140 µg/kg/min for 4 min), high dose (210 µg/kg/min for 4 min) and long dose (140 µg/kg/min for 8 min). 60 
patients with either known or suspected coronary artery disease (CAD) or with heart failure and different degrees of 
left ventricular (LV) dysfunction underwent adenosine stress with standard and high dose adenosine within the same 
scan. All studies were carried out on a 3 T CMR scanner. Quantitative global myocardial perfusion and haemodynamic 
response were compared between doses.
Results: In healthy controls, no significant difference was seen in stress MBF between the 3 protocols. In patients 
with known or suspected CAD, and those with heart failure and mild systolic impairment (LV ejection fraction 
(LVEF) ≥ 40%) no significant difference was seen in stress MBF between standard and high dose adenosine. In those 
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Introduction
Stress perfusion cardiovascular magnetic resonance 
(CMR) is an accurate, non-invasive technique for the 
detection of myocardial ischaemia [1, 2]. The method is 
widely used in the assessment of patients with suspected 
or known coronary artery disease (CAD); either to detect 
ischaemia, or in the context of cardiac dysfunction to 
detect an underlying ischaemic cause.
Intravenous adenosine has been shown to induce near 
maximal hyperaemia [3] and is used for assessment of 
ischaemia using both invasive measurements such as 
fractional flow reserve (FFR) and non-invasive tech-
niques including CMR and positron emission tomogra-
phy (PET). For stress perfusion CMR, adenosine is the 
most commonly used pharmacological stress agent [4]. 
Accepted protocols recommend administration of aden-
osine at a dose of 140 µg/kg/min with an increase up to 
210 µg/kg/min if required to achieve adequate stress [5]. 
The duration of adenosine infusion is standardised and 
usually given for at least 3 min prior to data acquisition, 
but it is not known if a longer duration or higher dose 
may produce a better response.
Conventionally, adequate stress is defined by a heart 
rate (HR) rise of ≥ 10  bpm or a systolic blood pressure 
(SBP) fall of > 10 mmHg [5], based on the assumption that 
coronary vasodilatation leads to systemic vasodilation 
and reflex tachycardia. Recent studies have suggested 
however, that these peripheral measurements may not 
be a true reflection of myocardial hyperaemia and should 
not be used to assess adenosine response [6, 7]. In addi-
tion, certain patient groups including those with heart 
failure and diabetes mellitus have a blunted haemody-
namic response to intravenous adenosine [8–10] and it is 
unclear to what extent this reduced response is reflected 
in coronary vasodilation.
Recently developed techniques of inline myocar-
dial perfusion mapping with CMR provide accurate, 
reproducible assessment of rest and vasodilator stress 
myocardial blood flow (MBF) following adenosine 
administration [11–13]. This study looked to compare 
stress MBF with different dosing regimens of adenosine 
during stress perfusion CMR in patients with suspected 
CAD, heart failure and healthy controls.
Methods
Study population
Twenty healthy subjects were recruited as controls to 
compare 3 adenosine perfusion protocols. Exclusion cri-
teria were any known cardiovascular disease, hyperten-
sion, hyperlipidaemia, diabetes mellitus, smoking, body 
mass index (BMI) > 30 and any contraindication to CMR, 
adenosine or gadolinium-based contrast agents.
Sixty patients with symptoms of angina or heart fail-
ure were recruited prospectively from CMR or coronary 
angiography waiting lists, for comparison of 2 adeno-
sine protocols determined from the results in healthy 
subjects. Patients were divided into three groups for 
analysis consisting of; Group 1—Patients with coronary 
artery disease and left ventricular (LV) ejection fraction 
(LVEF) ≥ 40%. Group 2—Mild to moderate heart failure, 
LVEF ≥ 40% and no evidence of coronary disease, and 
Group 3—Moderate to severe heart failure, LVEF < 40% 
and no evidence of CAD. Exclusion criteria for patients 
were the presence of any contraindication to CMR, aden-
osine or gadolinium-based contrast agents. CAD was 
defined by either ischaemic (subendocardial) late gado-
linium enhancement (LGE) on CMR, at least moderate 
stenosis on coronary angiography, previous percutane-
ous coronary intervention or previous coronary arterial 
bypass grafting.
Study protocol
All CMR studies were undertaken on a 3 T CMR system 
(Magnetom Prisma, Siemens Healthineers, Erlangen, 
Germany). Participants were advised to avoid caffeine 
for 24 h before the study. The protocol consisted of cine 
imaging, stress and rest perfusion, and LGE.
For perfusion imaging, adenosine was infused at a set 
dose for a preassigned time. Healthy subjects had three 
stress perfusion acquisitions; standard dose (140  µg/kg/
min adenosine for 4 min), high dose (210 µg/kg/min for 
4 min) and long dose (140 µg/kg/min for 8 min). Patients 
received standard dose and high dose for 4  min each. 
with LVEF < 40%, there was a significantly higher stress MBF following high dose adenosine compared to standard 
dose (1.33 ± 0.46 vs 1.10 ± 0.47 ml/g/min, p = 0.004). Non-responders to standard dose adenosine (defined by an 
increase in heart rate (HR) < 10 bpm) had a significantly higher stress HR following high dose (75 ± 12 vs 70 ± 14 bpm, 
p = 0.034), but showed no significant difference in stress MBF.
Conclusions: Increasing adenosine dose from 140 to 210 µg/kg/min leads to increased stress MBF in patients with 
significantly impaired LV systolic function. Adenosine dose in clinical perfusion assessment may need to be increased 
in these patients.
Keywords: Perfusion, Myocardial blood flow, Adenosine stress, Heart failure
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Doses were given in random order. A 10-min interval 
was kept between perfusion acquisitions, rest perfusion 
images were acquired 10 min after the final stress perfu-
sion sequence in all participants.
Participants were monitored for symptoms through-
out the scan. SBP and HR were recorded prior to starting 
adenosine infusion and before acquisition. For each per-
fusion acquisition, an intravenous bolus of 0.05  mmol/
kg gadobutrol (Gadovist, Bayer Healthcare, Berlin, Ger-
many) was administered at 5  ml/s followed by a 20  ml 
saline flush using an automated injection pump (Medrad 
MRXperion Injection System, Bayer Healthcare). Perfu-
sion mapping was performed and implemented on the 
scanner using the Gadgetron streaming software image 
reconstruction framework as previously described [11, 
13]. MBF maps were acquired as a short axis stack using 
a free-breathing, dual sequence, saturation recovery fast 
low angle shot (FLASH) protocol with motion correc-
tion. Three 8 mm slices were acquired, with slice spacing 
varied on a per patient basis to cover the left ventricle.
Analysis
Ischaemic segments were identified on visual assessment 
of perfusion images. Splenic switch off was assessed by 
comparing enhancement of splenic tissue at stress and at 
rest according to previously published methods [14, 15].
Perfusion maps were analysed using cvi42 software 
(Circle Cardiovascular Imaging, Calgary, Alberta, Can-
ada). Endocardial and epicardial borders were drawn 
excluding papillary muscles, right ventricular inser-
tion points marked, and a 16-segment American Heart 
Association model [16] used for further segmentation. 
In order to minimise partial volume effect, a 10% offset 
was applied to endocardial and epicardial borders [12]. 
MBF was recorded for each of the 16 segments. Where 
the LV outflow tract was included, or segments were too 
thin to contour, these segments were excluded from fur-
ther analysis. Segments with ischaemic (subendocardial) 
LGE were also excluded from analysis. MBF values for all 
remaining segments were averaged to provide a value for 
global MBF.
Subgroup analyses
Subgroup analysis was carried out comparing patients 
with a HR change of < 10  bpm (non-responders) com-
pared to those with a rise of ≥ 10  bpm (responders). 
Within Group 1, segments with ischaemia on vis-
ual assessment were compared with non-ischaemic 
segments.
Fig. 1 Results in healthy control group (n = 19). a Increase in heart rate (HR) between adenosine doses, b stress myocardial blood flow (MBF) 
between adenosine doses. In healthy subjects, no significant differences in MBF were seen between doses of adenosine despite significantly higher 
HR with high dose adenosine and long dose adenosine
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Statistical analysis
Analysis was performed using SPSS (version  23, Sta-
tistical Package for the Social Sciences, International 
Business Machines, Inc., Armonk, New York, USA). 
Normality of distribution was assessed using Shapiro–
Wilk test. Different dosing regimens were analysed using 
paired t-tests or Wilcoxson Signed Rank test in patients 
and analysis of variance (ANOVA) with repeated meas-
ures and post-hoc Bonferroni correction, or the Kruskal 
Wallis H test in healthy controls. Categorical data was 
analysed using chi-square test or Fisher’s exact test when 
expected numbers were < 5. All statistical tests were two-
tailed and p < 0.05 was considered significant.
Myocardial perfusion reserve (MPR) was calculated 
as stress MBF:rest MBF. Inadequate HR response was 
defined as < 10 bpm in keeping with Society for Cardio-
vascular Magnetic Resonance guidelines [5].
Results
Healthy controls
20 healthy control subjects were recruited (25 ± 2.7 years, 
LVEF 57 ± 3.3%). One subject withdrew after the first 
dose of adenosine. Haemodynamic data were available for 
all three dosing regimens for 19 healthy subjects. In one 
case artefact on perfusion maps at standard dose meant 
these were not included in analysis of MBF response. The 
final cohort therefore consisted of 18 subjects.
Haemodynamic response
Haemodynamic data are shown in Table  1. For all 
doses there was a significant rise in HR at stress from 
rest (p < 0.001). In both standard and long dose proto-
cols there was a significant increase in stress SBP from 
rest (p < 0.01). There was no significant change in SBP 
between rest and high dose adenosine. Only one partici-
pant had a SBP decrease of ≥ 10 mmHg at standard and 
high dose adenosine, and none had this degree of change 
with long dose.
There was a significant difference in stress HR and 
between standard and high dose adenosine, but no differ-
ence between standard and long dose. No significant dif-
ference was seen in SBP or change in SBP between doses.
MBF
Global stress MBF was 2.50 ± 0.74 ml/g/min with stand-
ard dose adenosine, with values of 2.66 ± 0.59 ml/g/min 
after high dose and 2.59 ± 0.64 ml/g/min with long dose, 
overall there was no significant difference between the 
three groups (p = 0.32).
Although there was no significant difference in MBF, 
the largest increases in HR were seen following the high 
Table 1 Haemodynamic response and MBF in healthy subjects
A significant difference was seen in stress heart rate and change in stress HR
HR heart rate, SBP systolic blood pressure, MBF myocardial blood flow, MPR myocardial perfusion reserve
* Significant difference between adenosine doses, †significant difference from rest value, p < 0.05 ‡significant difference from rest value, p < 0.01. Data given as 
mean ± standard deviation
Adenosine dosing
Standard dose: 140 µg/kg/min
4 min duration
High dose: 210 µg/kg/min
4 min duration
Long dose: 140 µg/kg/min
8 min duration
p
Rest HR (bpm) 71 ± 15 71 ± 14 71 ± 13 0.962
Rest SBP (mmHg) 117 ± 12 118 ± 14 117 ± 13 0.481
Stress HR (bpm) 102 ±  19† 108 ±  16† 106 ±  19† 0.017*
Stress SBP (mmHg) 121 ±  16† 121 ± 16 124 ±  17‡ 0.195
Change in HR (bpm) 30 ± 12 37 ± 11 35 ± 13 0.045*
Change in SBP (mmHg) 5 ± 6 3 ± 9 7 ± 11 0.072
Stress MBF (ml/g/min) 2.50 ± 0.74 2.66 ± 0.59 2.59 ± 0.64 0.323
MPR 3.52 ± 0.93 3.82 ± 0.83 3.72 ± 1.00 0.191
Table 2 Characteristics of patient groups
Other than left ventricular ejection fraction (LVEF), no significant difference was 
seen between the groups in factors previously reported to affect adenosine 
response
Data given as mean ± standard deviation or n (%)
Group 1—Patients with coronary disease and left ventricular ejection fraction 
(LVEF) > 40%. Group 2—Mild to moderate heart failure, LVEF ≥ 40% and no 
evidence of coronary artery disease. Group 3—moderate to severe heart failure, 
LVEF < 40% and no evidence of coronary artery disease
Group 1 Group 2 Group 3 p
n 20 16 24
Sex—male 17 (85%) 8 (50%) 17 (71%) 0.074
Age 62.9 ± 8.7 63.5 ± 16.3 65.1 ± 12.7 0.344
Diabetes mellitus 4 (20%) 0 6 (25%) 0.102
Beta blocker usage 14 (70%) 12 (75%) 17 (71%) 0.940
LVEF 57.5 ± 7.9 48.1 ± 5.2 26.2 ± 7.0 < 0.001
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dose regimen (Fig.  1), therefore this regime was chosen 
for comparison with standard dose in patients.
Patients
Sixty patients took part in the study divided into 20 in 
Group 1 (CAD), 16 in Group 2 (mild to moderate heart 
failure, LVEF ≥ 40%) and 24 in Group 3 (moderate to 
severe heart failure, LVEF < 40%). No significant differ-
ences were seen between the groups in incidence of dia-
betes mellitus, beta-blocker usage, age or sex (Table 2).
Haemodynamic response
Haemodynamic data are shown in Table  3. Mean stress 
HR increased significantly from mean rest HR in all 
groups and following both standard and high dose 
adenosine (p < 0.01). There was no significant change 
between stress and rest SBP in any group. In total, 36 
(60%) patients had a HR rise ≥ 10  bpm with standard 
dose adenosine, and 42 (70%) with high dose. One (2%) 
patient had a SBP decrease of ≥ 10 mmHg with standard 
dose, and 2 (3%) with high dose. In each group, there was 
a similar proportion of non-responders.
Fig. 2 While high dose adenosine did not result in significantly larger heart rate changes in any of the three groups of patients, high dose 
adenosine did improve stress MBF in patients with left ventricular ejection fraction (LVEF) < 40%
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Within group 1, stress HR was significantly higher fol-
lowing high dose compared with standard dose adenosine 
(78 ± 13 vs 75 ± 13 bpm, p = 0.025), but no significant dif-
ference was seen in groups 2 or 3. Stress SBP was signifi-
cantly lower following high dose adenosine compared to 
standard dose in group 2 (120 ± 13 vs 124 ± 11  mmHg, 
p = 0.005). There was no significant difference in stress 
SBP between doses in the other groups.
No significant difference was seen in absolute HR rise 
between the groups (Fig. 2) and no significant correlation 
was seen between LVEF and HR rise across all 60 patients 
(r = 0.122, p = 0.353).
MBF and MPR
No difference was seen in rest MBF between the 
3 groups (Group 1—0.73 ± 0.16  ml/g/min, Group 
2—0.71 ± 0.23  ml/g/min, Group 3—0.62 ± 0.16  ml/g/
min, p = 0.144). No difference was seen in MBF or MPR 
between different adenosine doses in either Group 1 or 
2. Within Group 3, MBF was significantly higher follow-
ing high dose than after standard dose adenosine (stand-
ard dose 1.10 ± 0.47 vs high dose 1.33 ± 0.46 µg/ml/min, 
p = 0.004) (Figs. 2, 3). MPR demonstrated the same pat-
tern (standard dose 1.90 ± 0.88 vs high dose 2.26 ± 0.90, 
p = 0.004).
Bland Altman plots (Fig. 4) show the spread of differ-
ences in MBF between adenosine doses and those with 
and without adequate response to adenosine at standard 
dose.
There were weak correlations between increase in HR 
and MPR both with standard (r = 0.266, p = 0.045) and 
high dose adenosine (r = 0.54, p < 0.001). HR response 
with standard dose adenosine did not correlate with an 
increase in MBF or MPR with high dose adenosine.
Five patients demonstrated failed splenic switch off 
with standard dose adenosine (Table  3). Analysis was 
repeated, excluding those with failed splenic switch off. 
These showed the same pattern with no difference in 
stress MBF or MPR between standard and high dose 
adenosine in Group 1 and Group 2, but higher stress 
MBF (1.15 ± 0.46 vs 1.38 ± 0.45, p = 0.009) and MPR 
(1.99 ± 0.88 vs 2.34 ± 0.91, p = 0.009) in Group 3.
Subgroup analyses
Heart rate response to adenosine
Patients were divided into groups of non-responders 
(n = 24) and responders (n = 36) based on a HR increase 
of < 10 bpm or ≥ 10 bpm. There was no significant differ-
ence in LVEF, age or incidence of diabetes or beta blocker 
usage between the two groups. Stress HR was signifi-
cantly different between groups both with standard and 
high dose adenosine (70 ± 14 vs 88 ± 15 bpm, p =  < 0.001 
at standard dose and 75 ± 12 vs 89 ± 18 bpm, p = 0.001 at 
high dose). There was no significant difference in rest HR 
or stress MBF between the two groups at either adeno-
sine dose.
In the non-responder group, stress HR was signifi-
cantly higher with high dose adenosine than with stand-
ard dose (Table 4). Those with adequate HR response to 
standard dose did not have a significant increase in stress 
HR between doses. No significant difference was seen in 
stress MBF between standard and high dose adenosine 
regardless of adequate HR response to standard dose 
adenosine.
Ischaemia
Within group 1, 11 patients had evidence of 
regional  inducible ischaemia. On visual analysis, ischae-
mia was seen in the same coronary territories between 
the adenosine doses. A total of 60 ischaemic segments 
were visually identified following standard dose adeno-
sine, and 63 segments following high dose. No signifi-
cant difference was seen in MBF in between standard and 
high dose adenosine in either the ischaemic (1.46 ± 0.30 
vs 1.48 ± 0.40 ml/g/min, p = 0.697) or non-ischaemic seg-
ments (1.72 ± 0.57 vs 1.77 ± 0.52 ml/g/min, p = 0.130) in 
these patients.
Discussion
The Society for Cardiovascular Magnetic Resonance 
Standardized (SCMR)   imaging protocols for stress per-
fusion recommend an adenosine dose of 140 μg/kg body 
weight/min for 2–4  min with an increase in the dose if 
there is inadequate HR and SBP response [5]. Our results 
inform several aspects of this recommendation: the dura-
tion of adenosine infusion, the dose of adenosine and the 
use of HR and SBP as indicators of adequate response. 
In healthy controls, increased dose or extended duration 
adenosine were not associated with significant changes 
in stress MBF compared with standard dose adenosine. 
Equally, in patients with normal or mildly impaired LV 
systolic function there was no effect of higher dose aden-
osine, but in those with moderate to severe LV systolic 
dysfunction (LVEF ≤ 40%), higher dose adenosine pro-
duced higher stress MBF. We further show that HR and 
SBP are unreliable markers of haemodynamic response.
Duration of adenosine infusion
The duration of adenosine infusion has not previously 
been studied for stress perfusion CMR but has been the 
subject of studies in nuclear cardiology. In Single Pho-
ton Emission Computed Tomography, a 3-min adenosine 
infusion showed better tolerability with similar diagnos-
tic performance compared with a 6-min protocol[17]. 
A PET study using Rb-82 compared several adenosine 
regimes in 127 subjects and found that a 6-min adenosine 
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Fig. 3 Difference in stress MBF between doses in three groups of patients. Within Group 3 (moderate-severe heart failure) stress MBF was 
significantly higher with high dose adenosine compared to standard dose
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Fig. 4 Difference in MBF between doses. ● represents adequate HR response to standard dose adenosine, x represents blunted response. In Group 
3, stress MBF is significantly higher following high dose adenosine, this effect does not appear to be related to HR response at standard dose
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infusion protocol with Rb-82 activation at 3  min was 
associated with 11.4% higher stress MBF and 15.7% 
higher coronary flow reserve (CFR) than a 4-min adeno-
sine infusion with Rb-82 activation at 2 min [18]. Further 
extension of the adenosine infusion time prior to Rb-82 
activation did not increase increased stress MBF or CFR 
further. These results are not directly applicable to CMR 
due to the differences in tracer kinetics and data capture 
between PET and CMR. Our data show that in myocar-
dial perfusion CMR, there is no significant difference in 
haemodynamic response and no change in quantitative 
MBF between a 4 min and an extended 8 min adenosine 
protocol in healthy subjects. These results suggest that 
the shorter duration protocols that are in current clinical 
use and recommended in current guidance are adequate 
for myocardial perfusion CMR.
Dose of adenosine infusion
The dose of adenosine infusion has been studied more 
extensively, using multiple modalities. Early invasive 
studies using intracoronary Doppler assessment of coro-
nary blood flow velocity and total coronary resistance 
showed that intravenous adenosine at doses of 140  µg/
kg/min resulted in maximal hyperaemia, defined by 
papaverine response, in 84% of subjects [3]. Several inva-
sive studies have assessed the effect of adenosine dose 
on FFR with higher doses showing no significant change 
in FFR compared with lower doses [19–21]. In a CMR 
study, Karamitsos et al. showed that a stepwise increase 
in the adenosine dose from 140 μg/kg/min to 210 μg/kg/
min is safe and increases the rate of patients with an ade-
quate haemodynamic response [22]. However, the MBF 
response to different adenosine doses has not previously 
compared using quantitative myocardial perfusion CMR. 
In addition to studying the same individuals repeatedly, 
we obtained MBF values at different adenosine doses in 
the same imaging session. This approach overcomes the 
potential confounders of day-to-day physiological varia-
tion in haemodynamic response and allows direct com-
parison of dose effects. Our data show no significant 
difference in MBF following standard and high dose 
adenosine in healthy subjects and patients with CAD or 
heart failure with LVEF ≥ 40%, suggesting that irrespec-
tive of haemodynamic response, standard dose adenosine 
in these groups reliably induces maximal hyperaemia.
Impaired LV systolic function
In patients with severe systolic impairment, previous 
studies have shown a blunted HR response to adeno-
sine, with an increase in adenosine from 140 to 210 µg/
kg/min more commonly required to achieve a sufficient 
haemodynamic response [8]. In CMR, a previous study 
reported LVEF < 57% as an independent predictor of 
inadequate haemodynamic response to standard adeno-
sine dose [22]. Within our patient cohort, there was no 
correlation between LVEF and HR rise, and no difference 
in HR rise between the patient groups, or any signifi-
cant difference in the rate of non-responders. However, 
our study showed for the first time that among patients 
with heart failure and significant LV systolic impairment 
(LVEF ≤ 40%), stress MBF increases with higher doses 
of adenosine, suggesting that standard dose regimes fail 
to induce maximal hyperaemia and are not appropri-
ate in these patients. A pattern of decreased response 
to adenosine in heart failure requiring higher doses to 
achieve stress has previously been suggested [8]. Poten-
tial mechanisms for the lower adenosine effect include 
the downregulation of gene expression of both adeno-
sine receptors and adenosine deaminase in impaired 
myocardium, together with a decrease in the activity of 
adenosine deaminase [23, 24]. Increased levels of car-
diac adenosine have also been measured in chronic heart 
failure patients, and this higher endogenous level may 
explain the requirement for higher exogenous doses to 
achieve the anticipated vasodilation required in stress 
testing [23, 24].
Haemodynamic response
In non-invasive testing, response to adenosine and the 
achievement of hyperaemia is commonly assessed using 
haemodynamic response relating to peripheral vasodila-
tion. Conventionally, an increase in HR by > 10 bpm and a 
fall in systolic SBP by > 10 mmHg are considered markers 
Table 4 Difference in response to adenosine doses divided by 
HR response to standard dose
Stress HR was significantly higher with high dose adenosine in the non-
responder group only. Non-responders and responders were defined by heart 
rate increase with adenosine of < 10 bpm or ≥ 10 bpm. There data are from 
patients only. No difference was seen in stress MBF in either group
Data given as mean ± standard deviation or n (%)
HR heart rate, MBF myocardial blood flow
Standard dose High dose p
Non-responders (n = 24)
Rest HR (bpm) 67 ± 16 68 ± 14 0.789
Stress HR (bpm) 70 ± 14 75 ± 12 0.034
Increase in HR (bpm) 3 ± 6 7 ± 11 0.053
Stress MBF (ml/g/min) 1.35 ± 0.49 1.45 ± 0.46 0.188
MPR 1.93 ± 0.77 2.05 ± 0.70 0.215
Adequate HR response (n = 36)
Rest HR (bpm) 69 ± 12 70 ± 13 0.461
Stress HR (bpm) 88 ± 15 89 ± 18 0.762
Increase in HR (bpm) 19 ± 9 19 ± 13 0.838
Stress MBF (ml/g/min) 1.48 ± 0.60 1.59 ± 0.43 0.103
MPR 2.32 ± 0.86 2.53 ± 0.63 0.073
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of adequate hyperaemia [5]. A small previous PET perfu-
sion study suggested a correlation between HR response 
and stress MBF [18], but confounders such as LVEF were 
not explicitly considered. In an earlier larger PET study, 
change in HR correlated poorly with stress MBF, and not 
with CFR, leading the authors to suggest that peripheral 
haemodynamic changes could not be used to assess the 
adequacy of response to adenosine [6]. No CMR studies 
have previously looked at haemodynamic response and 
change in quantitated MBF.
Within our study, 61% of those patients with 
LVEF > 40% reached the threshold of 10 bpm, comparable 
to published results in other studies with a similar patient 
group [8]. This relatively low response rate may be due 
to the presence of medications and other co-morbidities 
in our patient cohort. Blunted haemodynamic response 
to adenosine has been reported in diabetes, beta-blocker 
usage and CAD as well as impaired LVEF [8–10, 22, 25]. 
Increase in HR correlated only weakly with MPR and no 
significant difference was seen in stress MBF between 
groups classified by HR response.
This study showed no significant relationship between 
rise in HR at standard dose adenosine and an increase in 
stress MBF or MPR with high dose adenosine. This indi-
cates that in patients with a low HR response at standard 
dose adenosine, a higher dose does not increase myo-
cardial perfusion—a finding that questions the validity 
of current guideline recommendations and widely used 
clinical practice.
Further, we saw no significant difference in SBP change 
between groups of patients, or adenosine doses and < 3% 
of patients had a decrease in SBP of ≥ 10  mmHg as 
described in standard protocols. SBP even increased 
in healthy subjects over baseline. These data suggest, 
in keeping with previous studies, that in particular SBP 
response should not be used as a marker of adequate vas-
odilator response, possibly due to an adrenergic response 
to adenosine symptoms, which overcomes the vasodila-
tor effects on blood pressure.
Clinical implications
Our data suggest that those with reduced LVEF should 
have higher dose adenosine to achieve maximal hyper-
aemia, regardless of haemodynamic response. Our data 
also question the use of HR and SBP response to stand-
ard dose adenosine as criteria to increase the adenosine 
dose as it does not appear to increase MBF. However, due 
to low numbers of patients with inducible ischaemia in 
this study we have not been able to assess the diagnostic 
impact of our observations although we observed a small, 
non-significant, increase in the number of ischaemic seg-
ments identified following high dose adenosine.
Limitations
Our data may be influenced by physiological variation, 
although we have tried to minimise this. It is possible 
some effects may not have been controlled for, although 
we have previously demonstrated no significant dif-
ference in serial measurements of stress MBF within 
a CMR study [12]. Caffeine has been demonstrated to 
affect adenosine stress perfusion CMR [26]. Although we 
advised our subjects to avoid caffeine for 24 h prior to the 
scan, previous studies have demonstrated that up to 20% 
may still have detectable caffeine levels [27] and we can-
not account for how these may be distributed between 
our patient groups in this study. The age range of our 
healthy subjects was considerably lower than those of the 
patient groups, if age influences the response to adeno-
sine then the results from these healthy subjects may not 
be applied to our patient groups. There was no signifi-
cant difference in mean ages between the patient groups. 
Our data cannot exclude that a higher dose of adenosine 
than 210  µg/kg/min might further increase stress MBF 
in those with LVEF < 40%, but our data also cannot be 
extrapolated to support this possibility. Although the use 
of doses in excess of 210 mcg/kg/min are not used in rou-
tine practice, future studies should explore higher doses 
in particular in HF patients.
Conclusions
Increasing adenosine dose is well tolerated and related to 
increased stress myocardial blood flow in patients with 
significant LV impairment. Achievement of adequate 
myocardial vasodilator response, assessed by quantita-
tive perfusion, is not significantly related to peripheral 
haemodynamic measurements SBP and HR. These obser-
vations may impact future practice guidelines for stress 
perfusion CMR. Dosage of adenosine in clinical perfu-
sion assessment should be carefully considered and may 
need to be increased in subsets of patients, in particular 
those with severely impaired LV function, or alternative 
stress agents considered.
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